Trial
NCT03473691
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
Early Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Virginia
Collaborators
Celldex Therapeutics
Condition
Triple Negative Breast Cancer
Intervention
Glembatumumab Vedotin
Why stopped
Pharmaceutical company decided to withdraw funding and not provide drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-09